Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2019; 9(03): 107-110
DOI: 10.4103/ajm.AJM_189_18
BRIEF REPORT

Overprescription of antibiotics in patients with community-acquired pneumonia in the intensive care unit

Rorak Hooten
Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA
,
Jose Luis Marquez
Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA
,
Kady Goldlist
Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA
,
Rafael Urcis
Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA
,
Matthew Adams
Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA
,
Kathryn Matthias
Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA
,
David Nix
Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA
,
Mayar Al Mohajer
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Purpose: We aimed to assess factors associated with therapy failure in patients with community-acquired pneumonia in the intensive care unit (ICU). Methods: Electronic charts of patients with International Classification of Diseases, Ninth Revision, codes of pneumonia who were admitted to the ICU at a tertiary academic medical center in Southern Arizona were reviewed. Results: Antipseudomonal coverage and anti-methicillin-resistant Staphylococcus aureus (MRSA) coverage were often prescribed (58.4% and 54.1%, respectively). Antipseudomonal coverage was rarely necessary as pseudomonal pneumonia was found in only one case (0.9%). Antipseudomonal and anti-MRSA coverage was not associated with improved outcomes. Conclusion: Overprescription of antibiotics in this population remains a significant problem. More work is needed to further limit unnecessary antibiotic use.

Keywords

Antimicrobials - incentive care unit - outcomes - overuse - respiratory infection


Publication History

Article published online:
09 August 2021

© 2019. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. JAMA 2000; 283: 749-55
    CrossrefPubMedGoogle Scholar
  • 2 Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T. et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant staphylococcus aureus carrying the panton-valentine leukocidin genes. Clin Infect Dis 2005; 40: 100-7
    CrossrefPubMedGoogle Scholar
  • 3 Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JD, Bridges CB. et al. Severe community-acquired pneumonia due to staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12: 894-9
    CrossrefPubMedGoogle Scholar
  • 4 Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza—Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007;56:325-9.
  • 5 Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ. et al. ; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55
    CrossrefPubMedGoogle Scholar
  • 6 Giancola SE, Nguyen AT, Le B, Ahmed O, Higgins C, Sizemore JA. et al. Clinical utility of a nasal swab methicillin-resistant Staphylococcus aureus polymerase chain reaction test in intensive and intermediate care unit patients with pneumonia. Diagn Microbiol Infect Dis 2016; 86: 307-10
    CrossrefPubMedGoogle Scholar
  • 7 Dangerfield B, Chung A, Webb B, Seville MT. et al. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother 2014; 58: 859-64
    CrossrefPubMedGoogle Scholar